Phase 1/2 × Recruiting × Carcinoma, Transitional Cell × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
NCT06943521 2025-12-11

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America, Inc.

Phase 1/2 Recruiting
27 enrolled